Treatment of dementia with neurotransmission modulation

  title={Treatment of dementia with neurotransmission modulation},
  author={Sheila Anne Doggrell and Suzanne Evans},
  journal={Expert Opinion on Investigational Drugs},
  pages={1633 - 1654}
  • S. Doggrell, S. Evans
  • Published 1 October 2003
  • Biology, Medicine, Psychology
  • Expert Opinion on Investigational Drugs
The prevalence of dementia is growing in developed countries where elderly patients are increasing in numbers. Neurotransmission modulation is one approach to the treatment of dementia. Cholinergic precursors, anticholinesterases, nicotine receptor agonists and muscarinic M2 receptor antagonists are agents that enhance cholinergic neurotransmission and that depend on having some intact cholinergic innervation to be effective in the treatment of dementia. The cholinergic precursor choline… 
Galantamine Delivery for Alzheimer’s Disease
Even though the correct pathogenesis is not clear, decline in cholinergic neurotransmission remains the universal neurochemical fact in the pharmacology of Alzheimer’s, therefore, cholinesterase inhibitors e.g. rivastigmine, donepezil, galantamine etc. remains the primary choice for treatment as they elevate the acetylcholine quantity in the synaptic cleft, which further leads to upsurge inCholinergic transmission in brain.
Recent important trials of pharmacotherapy in Parkinson’s disease
  • S. Doggrell
  • Biology, Psychology
    Expert opinion on pharmacotherapy
  • 2005
The results of the clinical outcome part of the Earlier Versus Later Levodopa Therapy in PD study suggest that levodopa slows the progression of PD, and the single photon emission-computed tomography imaging substudy was not conclusive but suggested thatlevodopa hastened the progress of PD.
Cholinergic components of frontal lobe function and dysfunction.
Prospects Of Pharmacological Treatment Of Vascular Dementia In Patients With Arterial Hypertension
A reliable nootropic effect of the drug was revealed, as well as its effect on cerebrosthenic and somatovegetative manifestations.
Galantamine Prolonged-Release Formulation in the Treatment of Mild to Moderate Alzheimer’s Disease
Galantamine PRC had similar tolerability and safety profiles compared with twice-daily galantamine, and when administered as a once-daily flexible dosing regimen of 16 or 24 mg/day, was demonstrated to be as safe and effective for the treatment of mild to moderate AD.
Molecular Pathogenesis of Alzheimer's Disease: An Update
The main underlying neurobiological mechanisms in AD are summarized, including the theory with emphasis on amyloid peptide, cholinergic hypothesis, glutamatergic neurotransmission, the role of tau protein, and the involvement of oxidative stress and calcium.
Muscarinic receptor subtype pharmacology and physiology.
  • R. Eglen
  • Biology, Medicine
    Progress in medicinal chemistry
  • 2005
GABAergic systems in a model of age-related cognitive impairment
A rat model of cognitive aging was used to investigate the GABAergic neurotransmitter system in relation to changes in learning and memory functions and found some aged rats performed on par with young and others performed outside the range of young, demonstrating impairment (aged-impaired).


Nicotinic receptors in aging and dementia.
Activation of neuronal nicotinic acetylcholine receptors (nAChRs) has been shown to maintain cognitive function following aging or the development of dementia. Nicotine and nicotinic agonists have
Choline alphoscerate in cognitive decline and in acute cerebrovascular disease: an analysis of published clinical data
Efficacy and safety of nicotine on Alzheimer's disease patients.
A systematic review of unconfounded, double-blind, randomized trials in which treatment with nicotine patches or administration of nicotine intravenously or in any other way or form was administered for more than a day and compared with placebo for people with Alzheimer's disease fails to provide any evidence that nicotine is a useful treatment for Alzheimer’s disease.
Psychosis of Alzheimer’s disease is associated with elevated muscarinic M2 binding in the cortex
A role for M2 receptors in the psychosis of AD is suggested and may provide the rationale for treatment of behaviorally perturbed patients with AD with cholinomimetics and M2 antagonists.
Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa
Results obtained with a RIA for somatostatin are reported, showing that som atostatin-like immunoreactivity in the cerebral cortex is reduced in tissue from AD/SDAT patients.